1. Home
  2. JCE vs CUE Comparison

JCE vs CUE Comparison

Compare JCE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

N/A

Current Price

$16.96

Market Cap

288.2M

Sector

Finance

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$25.60

Market Cap

233.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JCE
CUE
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.2M
233.5M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
JCE
CUE
Price
$16.96
$25.60
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $88.00
AVG Volume (30 Days)
23.2K
★ 353.1K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.11
EPS
★ N/A
N/A
Revenue
N/A
★ $27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 195.75
52 Week Low
$13.99
$0.17
52 Week High
$17.45
$45.50

Technical Indicators

Market Signals
Indicator
JCE
CUE
Relative Strength Index (RSI) 50.17 42.64
Support Level $16.75 $23.51
Resistance Level $17.11 $33.11
Average True Range (ATR) 0.27 4.91
MACD -0.00 -0.83
Stochastic Oscillator 62.05 11.41

Price Performance

Historical Comparison
JCE
CUE

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Share on Social Networks: